Neame P B, Soamboonsrup P, Leber B, Carter R F, Sunisloe L, Patterson W, Orzel A, Bates S, McBride J A
Department of Laboratory Medicine, Hamilton Health Sciences Corporation, Ontario, Canada.
Am J Hematol. 1997 Nov;56(3):131-42. doi: 10.1002/(sici)1096-8652(199711)56:3<131::aid-ajh1>3.0.co;2-z.
Early diagnosis of t(15;17) acute promyelocytic leukemia (APL) is essential because of the associated disseminated intravascular coagulation and the unique response of the disease to all-trans retinoic acid (ATRA) therapy. Early diagnosis depends primarily on morphological recognition. The French-American-British (FAB) classification, however, does not describe all morphological variations that occur in APL. In 25 cases with evidence of APL confirmed by cytogenetic and/or molecular analysis, we found a heterogeneous morphological group. The most common form of APL was heterogeneous and consisted of various combinations of cells in which hypergranular cells and some cells with multiple Auer rods were obvious. In some cases, one cell predominated. This led to the description of five subcategories. These included the classical FAB M3 with hypergranular cells and multiple Auer rods; the FAB variant with hypogranular bilobed cells; the basophilic cell type of McKenna et al. [Br. J. Haematol 50:201, 1982]; and two additional subtypes, one consisting of differentiated promyelocytes and a few blast cells (M2-like), and the other consisting largely of blast cells and a few early promyelocytes (M1-like). Immunophenotyping revealed a pattern of CD33 and/or CD13 positivity, and CD14 and HLA-DR negativity in 96% of cases. CD2 was positive in the FAB variant and in the subtype with basophilic cells, but negative with other subtypes. Three out of five cases with basophilic cell predominance [McKenna et al.: Br J Haematol 50:201, 1982], and one out of two M2-like cases, responded to ATRA therapy. Awareness of the heterogeneity and the atypical morphologic subtypes found in t(15;17) APL will contribute to improved recognition and early institution of ATRA therapy.
由于t(15;17)急性早幼粒细胞白血病(APL)常伴有弥散性血管内凝血,且该疾病对全反式维甲酸(ATRA)治疗有独特反应,因此早期诊断至关重要。早期诊断主要依赖形态学识别。然而,法美英(FAB)分类并未描述APL中出现的所有形态学变异。在25例经细胞遗传学和/或分子分析证实为APL的病例中,我们发现了一个形态学异质性群体。APL最常见的形式是异质性的,由各种细胞组合构成,其中颗粒增多的细胞和一些有多个Auer小体的细胞很明显。在某些病例中,一种细胞占主导。这导致了五个亚类的描述。这些亚类包括具有颗粒增多细胞和多个Auer小体的经典FAB M3;具有颗粒减少的双叶细胞的FAB变异型;McKenna等人[《英国血液学杂志》50:201, 1982]描述的嗜碱性细胞类型;以及另外两个亚型,一个由分化的早幼粒细胞和少数原始细胞组成(M2样),另一个主要由原始细胞和少数早幼粒细胞组成(M1样)。免疫表型分析显示,96%的病例呈现CD33和/或CD13阳性,CD14和HLA-DR阴性。CD2在FAB变异型和嗜碱性细胞亚型中呈阳性,但在其他亚型中呈阴性。五例以嗜碱性细胞为主的病例[McKenna等人:《英国血液学杂志》50:201, 1982]中有三例,以及两例M2样病例中有一例对ATRA治疗有反应。认识到t(15;17) APL中的异质性和非典型形态学亚型将有助于提高识别率并尽早开始ATRA治疗。